A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-17. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
==== Race ==== Mental health impacts individuals of all ethnic and racial backgrounds across the world. Asian Americans often experience extreme levels of self-stigma, created from the intersection of cultural and societal factors. Cultural pressures lead to self-isolation and shame surrounding the inability to exceed expectations and maintain high achievement. Latino Americans face societal discrimination and report heightened levels of shame when speaking about mental health struggles. Latino communities face structural barriers such as documentation, low rates of English proficiency, and difficulties understanding the steps needed to navigate the healthcare system, ultimately limiting accessibility to mental health services. Latino men often face deep-rooted shame regarding mental health issues due to the cultural expectation of leading communities or a household. Immigration status, language barriers, or cultural beliefs cause many Latino Americans to avoid seeking professional care. The stigma surrounding mental health results in delayed professional care, embarrassment, and social rejection.
== Definition == Medication is a medicine or a chemical compound used to treat or cure illness. According to Encyclopædia Britannica, medication is "a substance used in treating a disease or relieving pain". As defined by the National Cancer Institute, dosage forms of medication can include tablets, capsules, liquids, creams, and patches. Medications can be administered in different ways, such as by mouth, by infusion into a vein, or by drops put into the ear or eye. A medication that does not contain an active ingredient and is used in research studies is called a placebo. In Europe, the term is "medicinal product", and it is defined by EU law as:
=== Via biodegradation of trifluomethyl compounds === Trifluoroacetic acid is not produced biologically, but it is a breakdown product of various organofluorine compounds, e.g., the volatile anesthetic agent halothane. It also may be formed by hydroxyl radical-initiated atmospheric oxidation of the commonly used refrigerant 1,1,1,2-tetrafluoroethane (R-134a). Moreover, it is formed as an atmospheric degradation product of almost all fourth-generation synthetic refrigerants, also called hydrofluoroolefins (HFO), such as 2,3,3,3-tetrafluoropropene. Trifluoroacetic acid is also formed by the degradation of some pesticides that contain a trifluoromethyl group (-CF3), such as flufenacet. The German Environment Agency estimated that pesticide use releases approximately 500 metric tonnes of TFA annually in Germany alone, while refrigerants account for around 1170 metric tonnes per year.
Sources: en.wikipedia.org
=== Freeze drying === Freeze drying is accomplished by lowering the pressure in a chamber containing the wood to a few millibars, while lowering the temperature of the chamber to below the eutectic point of the material. Heat is typically added slowly to the material to allow the water contained in the wood to sublimate directly into vapor, and be deposited on the sides of the vacuum chamber or in the cold trap through which the chamber is evacuated. Freeze drying through sublimation typically takes about 10 times the energy that is taken through evaporation of water by heat. In practice, freeze drying of wood can be accomplished by placing room temperature wood in a vacuum chamber that can be chilled to -30 degrees C or lower, evacuating the chamber to a few millibars, and at the same time cooling the chamber to a freezing temperature. The latent heat of the ice in the wood will come out through the water vapor, which will condense as ice on the inside of the chamber. After a few hours under vacuum and freezing conditions, the chamber is returned to normal pressure, the wood removed and bagged in plastic to keep water from condensing on it, and allowed to return to room temperature over a few hours to a day. The cycle is then repeated, each time the latent heat in the wood is removed through the water content in the wood sublimating and/or evaporating and condensing on the sides of the container and in the cold trap. The cycles are repeated until the moisture content of the wood is at a pre-determined acceptable level.
==== 1952–53 ==== When he joined the Cardinals, broadcaster Harry Caray started calling him "Vinegar Bend," and the nickname stuck. He was hailed as "the left-handed Dizzy Dean" by sportswriter Red Smith, which Mizell called "a perty heavy load for a boy to tote." Added to St. Louis's starting rotation for the 1952 campaign, Mizell made his major league debut on April 22 against the Cincinnati Reds. He gave up two runs in the first inning, then held the Reds scoreless for the rest of the game, though he took the loss in a 2–1 defeat. Two starts later, on May 2, he limited the Philadelphia Phillies to four hits and two runs in a complete game, winning in the ninth when Peanuts Lowrey broke a 2–2 tie with an RBI-single. After that win, he lost three games in a row, then received four consecutive no decisions. He ended the winless streak on June 21, when he struck out 11 in his first major league shutout against the Boston Braves. That started a streak of six decisions won in a row, during which time Mizell posted a 3.05 ERA. He would not lose again until August 27. On September 5, he threw his second shutout of the year, tying his season high with 11 strikeouts in a 4–0 victory over the Pittsburgh Pirates. Mizell finished his rookie season with a 10–8 record and a 3.65 ERA in 30 starts. He led the National League (NL) in strikeouts per 9 innings pitched with a 6.9 mark, and his 146 strikeouts ranked fourth in the league (behind Warren Spahn's 183, Bob Rush's 157, and Robin Roberts's 148). However, he also led the league in walks (103, tied with Herm Wehmeier).
When Victoria regains consciousness, she comes across a group of survivors who blame her for the destruction of the town and decide to leave. Saddened that the people she saved have come to hate her, Victoria wonders what to do next. The vision of her mother suggests that she should return to India and find her real mother, who may still be alive.
Margot lived at the foot of Canyon Mountain, right outside of Livingston. Like much of Montana, the mountain was filled with wolves. But instead of fearing them, Margot loved them. She left meat out for the wolves so she could watch them come down the mountain and eat from the safety of her home ... She'd asked her closest friends—if they stopped by her place and found her dead—to tell no one, place her naked body in a bedsheet, drag it up Canyon Mountain, and leave her for her other friends, the wolves. Kidder's body was cremated, and the ashes were scattered by her brother John in her favorite childhood locations in Canada, as well as in Montana, amongst lilies which were frequently eaten by grizzly bears, partially fulfilling Kidder's wish to "have her body just left out there for the bears."
Sources: en.wikipedia.org
Immunofluorescence is performed by the production of anti-antibodies with a fluorescent molecule attached, making it a chemiluminescent molecule, which provides a glow when subject to ultraviolet light. Antibodies are added to a bacterial solution, providing an antigen for the binding of fluorescent anti-antibody adherence.
The genetic code translates mRNA nucleotide sequences to amino acid sequences. Genetic information is coded using this process with groups of three nucleotides along the mRNA which are commonly known as codons. The set of three nucleotides almost always produce the same amino acid with a few exceptions like UGA which typically serves as the stop codon but can also encode tryptophan in mammalian mitochondria. Most amino acids are specified by multiple codons demonstrating that the genetic code is degenerate–different codons result in the same amino acid. Codons that code for the same amino acid are termed synonyms. Silent mutations are base substitutions that result in no change of the amino acid or amino acid functionality when the altered messenger RNA (mRNA) is translated. For example, if the codon AAA is altered to become AAG, the same amino acid – lysine – will be incorporated into the peptide chain. Mutations are often linked to diseases or negative impacts but silent mutations can be extremely beneficial in creating genetic diversity among species in a population. Germ-line mutations are passed from the parent to the offspring. Scientists have predicted that people have approximately 5 to 10 deadly mutations in their genomes but this is essentially harmless because there is usually only one copy of a particular bad gene so diseases are unlikely. Silent mutations can also be produced by insertions or deletions, which cause a shift in the reading frame.
=== Blotting === Western blotting can be used in order to quantify the abundance of certain proteins. By using antibodies specific to the protein of interest, it is possible to probe for the presence of specific proteins from a mixture of proteins.
Peptide hormones GHRH (somatocrinin) through binding to the growth hormone-releasing hormone receptor (GHRHR) Ghrelin through binding to growth hormone secretagogue receptors (GHSR) Sex hormones Increased androgen secretion during puberty (in males from testes and in females from adrenal cortex) Testosterone and DHEA Estrogen Clonidine, moxonidine and L-DOPA by stimulating GHRH release α4β2 nicotinic agonists, including nicotine, which also act synergistically with clonidine or moxonidine. Hypoglycemia, arginine, pramipexole, lysine, tryptophan, γ-Aminobutyric acid and propranolol by inhibiting somatostatin release Deep sleep Glucagon Sodium oxybate or γ-Hydroxybutyric acid Niacin as nicotinic acid (vitamin B3) Fasting Insulin Vigorous exercise Inhibitors of GH secretion include:
=== Government and NGO reports === National Drug Threat Assessment 2009 from the United States Department of Justice War On Drugs: Legislation in the 108th Congress and Related Developments, a 2003 report from the Congressional Research Service via the State Department website The Report of the Canadian Government Commission of Inquiry into the Non-Medical Use of Drugs – 1972 Drug Enforcement Administration (2017), Drugs of abuse: A DEA resource guide (PDF) (2017 ed.), Washington, D.C.: Author, archived from the original (PDF) on December 3, 2016, retrieved January 23, 2018 Revealing the missing link to Climate Justice: Drug Policy, a 2023 report from the International Coalition on Drug Policy Reform and Environmental Justice
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.